drugset / Trial / NCT01508572

VEGF-targeted Fluorescent Tracer Imaging in Breast Cancer

NCT01508572 ↗

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the uptake, (semi-)quantification and localization of the VEGF targeting fluorescent tracer bevacizumab-IDRye800CW in breast cancer tissue, surrounding healthy tissue, tumor margins and lymph nodes. This is measured in surgical specimens after a single intravenous administration of 4,5 bevacizumab-IDRye800CW, using fluorescence microscopy and macroscopy techniques. Also the safety of bevacizumab-IDRye800CW is assessed. Another purpose is to assess the abilities of three different fluorescent signal detection systems to detect the fluorescent signal pre- and intra-operatively.

Timeline

Start
2011-10
Primary completion
2014-11
Completion
2015-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Bevacizumab-IRDye800CW Monoclonal antibody 4.5 mg Intravenous

Indications